Together, these data indicate that depending on the tumor type, TRIM25 can exert opposing activities on ferroptosis, either positively via promoting proteasomal degradation of endogenous ferroptosis suppressors, or negatively by activation of USP/TRIM25/Keap1 axis and subsequent expression of ARE-driven antioxidant genes. This evidence concerns the gene KEAP1 and neoplasm.